<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04287491</url>
  </required_header>
  <id_info>
    <org_study_id>20190653</org_study_id>
    <nct_id>NCT04287491</nct_id>
  </id_info>
  <brief_title>Use Of Virtual Reality For Pain Control in Dermatological Bedside Procedures</brief_title>
  <official_title>Use Of Virtual Reality For Pain Control in Dermatological Bedside Procedures</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Miami</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Miami</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this research study is to explore the impact of virtual reality (VR) on pain
      perception during out-patient procedures such as wart removal, wound debridement, and
      lidocaine injections.
    </textblock>
  </brief_summary>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    Lack of funding
  </why_stopped>
  <start_date type="Anticipated">January 1, 2021</start_date>
  <completion_date type="Anticipated">April 1, 2022</completion_date>
  <primary_completion_date type="Anticipated">April 1, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in average pain as assessed by the visual analog scale (VAS)</measure>
    <time_frame>Baseline, up to 2 hours</time_frame>
    <description>VAS has a scoring range from 0 to 10 with 0 being no pain and 10 being the worst possible pain.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in maximum pain level as assessed by VAS</measure>
    <time_frame>Baseline, up to 2 hours</time_frame>
    <description>VAS has a scoring range from 0 to 10 with 0 being no pain and 10 being the worst possible pain.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in heart rate</measure>
    <time_frame>Baseline, up to 2 hours</time_frame>
    <description>Heart rate will be assessed in beats per minute.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in oxygen saturation</measure>
    <time_frame>Baseline, up to 2 hours</time_frame>
    <description>Oxygen saturation will be assessed as a percentage.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of intervention related adverse events</measure>
    <time_frame>Baseline, up to 2 hours</time_frame>
    <description>Intervention related adverse events will be assessed per treating physician discretion.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Pain</condition>
  <arm_group>
    <arm_group_label>Virtual Reality Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>This group will receive the virtual reality intervention during out-patient bedside procedures.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Oculus Go Virtual Reality System</intervention_name>
    <description>The VR system will provide a 3D environment that provides distracting stimulus. Participant will put on the Oculus Go VR system headset 1-2 minutes prior to out-patient bedside procedure up to the completion of procedure which takes typically 3-5 minutes.</description>
    <arm_group_label>Virtual Reality Group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients 13 years and older.

          -  Patient (or health care proxy when applicable) must sign an ICF.

          -  Patient requiring any painful dermatological bedside procedure including: wound
             debridement, injections and liquid nitrogen application.

          -  Patients willing to participate and parents able to consent.

        Exclusion Criteria:

          -  Subjects with a diagnosis of vertigo, inner ear diseases or seizures are excluded due
             to the uncertainty of performance under VR conditions.

          -  Subjects requiring procedures on the head are also excluded to the interference of the
             VR headset.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>13 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hadar Lev-Tov, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Miami</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Miami</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>February 25, 2020</study_first_submitted>
  <study_first_submitted_qc>February 25, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">February 27, 2020</study_first_posted>
  <last_update_submitted>June 12, 2020</last_update_submitted>
  <last_update_submitted_qc>June 12, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 16, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Miami</investigator_affiliation>
    <investigator_full_name>Hadar Lev-Tov</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

